Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Natoni

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
EMBO Reports|September 6, 2005
Calicivirus translation initiation requires an interaction between VPg and eIF 4 EIan Goodfellow, Yasmin Chaudhry, Ioanna Gioldasi, et al.
Molecular Cancer Therapeutics|July 20, 2011
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cellsAlessandro Natoni, Laura S Murillo, Anna E Kliszczak, et al.
Haematologica|May 19, 2019
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse modelAlessandro Natoni, Mariah L Farrell, Sophie Harris, et al.
Blood Advances|March 16, 2022
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responsesJohn Daly, Subhashis Sarkar, Alessandro Natoni, et al.
British Journal of Haematology|October 10, 2007
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2Alessandro Natoni, Marion MacFarlane, Satoshi Inoue, et al.
Cancers|November 9, 2013
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular ModelsAlessandro Natoni, Mark R E Coyne, Alan Jacobsen, et al.
Haematologica|February 13, 2023
Sialylation regulates migration in chronic lymphocytic leukemiaAlessandro Natoni, Marina Cerreto, Maria Stefania De Propris, et al.
Biochemistry|February 25, 2009
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptorsCarlos R Reis, Almer M van der Sloot, Eva Szegezdi, et al.
Cancer Immunology, Immunotherapy : CII|January 11, 2020
The CD38<sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16<sup>F158V</sup> in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricideSubhashis Sarkar, Sachin K S Chauhan, John Daly, et al.
Plos One|June 6, 2014
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage responseJennifer FitzGerald, Laura S Murillo, Gemma O'Brien, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
EMBO Reports|September 6, 2005
Calicivirus translation initiation requires an interaction between VPg and eIF 4 EIan Goodfellow, Yasmin Chaudhry, Ioanna Gioldasi, et al.
Molecular Cancer Therapeutics|July 20, 2011
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cellsAlessandro Natoni, Laura S Murillo, Anna E Kliszczak, et al.
Haematologica|May 19, 2019
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse modelAlessandro Natoni, Mariah L Farrell, Sophie Harris, et al.
Blood Advances|March 16, 2022
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responsesJohn Daly, Subhashis Sarkar, Alessandro Natoni, et al.
British Journal of Haematology|October 10, 2007
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2Alessandro Natoni, Marion MacFarlane, Satoshi Inoue, et al.
Cancers|November 9, 2013
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular ModelsAlessandro Natoni, Mark R E Coyne, Alan Jacobsen, et al.
Haematologica|February 13, 2023
Sialylation regulates migration in chronic lymphocytic leukemiaAlessandro Natoni, Marina Cerreto, Maria Stefania De Propris, et al.
Biochemistry|February 25, 2009
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptorsCarlos R Reis, Almer M van der Sloot, Eva Szegezdi, et al.
Cancer Immunology, Immunotherapy : CII|January 11, 2020
The CD38<sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16<sup>F158V</sup> in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricideSubhashis Sarkar, Sachin K S Chauhan, John Daly, et al.
Plos One|June 6, 2014
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage responseJennifer FitzGerald, Laura S Murillo, Gemma O'Brien, et al.
Pageof 3